BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Alpelisib: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Novartis Pharmaceuticals, Stemline Therapeutics, Inc., Hoffmann-La Roche, Celcuity Inc. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-27 est.P1/P2Stemline Therapeutics, Inc.NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerBreast Cancer; Metastatic Breast Canceractive not recruiting435
2027-01-28 est.P3Novartis Pharmaceuticals NVSNCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After TreatmBreast Canceractive not recruiting210
2027-01-29 est.P2Novartis Pharmaceuticals NVSNCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women WitBreast Neoplasmsactive not recruiting69

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P3Hoffmann-La RocheNCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-NegatiBreast Cancerrecruiting420
2026-06-30 est.P3Celcuity Inc CELCNCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (Breast Canceractive not recruiting701

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.